<List><item><source>MED</source><extId>30287621</extId><pmcid>PMC6395339</pmcid><annotations><annotation><prefix>-A01395-38, EUDRACT </prefix><exact>2012-002990-73</exact><postfix>38) and the study wa</postfix><tags><tag><name>2012-002990-73</name><uri>http://identifiers.org/euclinicaltrials/2012-002990-73</uri></tag></tags><id>http://europepmc.org/articles/PMC6395339#europepmc-ce058d4d244fee06741a3c056ab5b5e5</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>EUDRACT</subType></annotation><annotation><prefix>nki Declaration and registered in  as </prefix><exact>NCT03598582</exact><postfix>. </postfix><tags><tag><name>NCT03598582</name><uri>http://identifiers.org/clinicaltrials/NCT03598582</uri></tag></tags><id>http://europepmc.org/articles/PMC6395339#europepmc-bcd6e9c028c3dd0268cf1d08240f626b</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> to treatment with ESA ( identifier: </prefix><exact>NCT03387475</exact><postfix>). </postfix><tags><tag><name>NCT03387475</name><uri>http://identifiers.org/clinicaltrials/NCT03387475</uri></tag></tags><id>http://europepmc.org/articles/PMC6395339#europepmc-4aa14c19d8b1d2a7e4cca28f8aeb4da7</id><type>Accession Numbers</type><section>Discussion (http://purl.org/orb/Discussion)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ocardial iron overload ( identifier: </prefix><exact>NCT03381833</exact><postfix>). </postfix><tags><tag><name>NCT03381833</name><uri>http://identifiers.org/clinicaltrials/NCT03381833</uri></tag></tags><id>http://europepmc.org/articles/PMC6395339#europepmc-f33a1f096f508b1657fb29622dcb11cd</id><type>Accession Numbers</type><section>Discussion (http://purl.org/orb/Discussion)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>